A vaccine against hepatitis E was recently deployed to quench an outbreak at a displaced persons’ camp in South Sudan. Could it soon be used more broadly?

Norovirus, sometimes known as the “winter vomiting bug”, is common this time of year.

A high-level mission comprising Gavi, the Vaccine Alliance, the WHO, UNICEF, Bill & Melinda Gates Foundation and World Bank is scheduled to visit the Republic of Mozambique from 10 December, aiming to renew political commitment towards…

To a Nigerian community of some 10,000 people, the king is also the physician on call

People who usually suffer from allergies are most at risk.

Fatigue is the most commonly reported symptom among COVID-19 survivors in Africa.

A new study links nanoplastics to Parkinson's disease, suggesting they may trigger brain changes linked to the condition and some types of dementia. 

Muhammad Kamran lives with the lasting effects of a preventable infection. He’s doing what he can to make sure others won’t have to.

A new innovative financing instrument, called the African Vaccine Manufacturing Accelerator (AVMA), has been approved by the Gavi Board. But why is it important for African countries to produce vaccines, how will it work, and why now?

Gavi’s Board today approved the establishment of the African Vaccine Manufacturing Accelerator (AVMA), a financing instrument that will make up to US$ 1 billion available to support sustainable vaccine manufacturing in Africa.

Half of coastal Ayetoro is submerged as sea levels rise. Residents of the town known as “Happy City” are doing what they can to keep their spirits up and their health intact.

Delivering birth doses of hepatitis B vaccine will not only protect against liver disease, but strengthen countries’ ability to deliver other routine vaccinations.